SELLAS Life Sciences reports FY2022 net loss $41.3M; cash $17.1M, raised $20M in Feb 2023 plus $13M milestone expected

SELLAS Life Sciences Group, Inc.

Net loss $41.3M ($2.13 per share) vs $20.7M loss ($1.34 per share) in 2021.
Cash $17.1M at Dec 31, 2022; subsequent $20M public offering gross proceeds in Feb 2023.
Phase 3 REGAL AML study interim analysis expected late 2023/early 2024.
$13M milestone payment from 3D Medicines expected in H1 2023.
Phase 1 of CDK9 inhibitor GFH009 shows no dose-limiting toxicities; first confirmed CR in AML.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SELLAS Life Sciences Group, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 16, 2023, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2022 and providing a corporate update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001390478-23-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.